Abstract
NOD mice have a relative deficiency of CD4+CD25+ regulatory T cells that could result in an inability to maintain peripheral tolerance. The aim of this study was to induce the generation of CD4+CD25+ regulatory T cells in response to autoantigens to prevent type 1 diabetes (T1D). We found that immunization of NOD mice with insulin B-chain peptide B:9-23 followed by 72 h in vitro culture with B:9-23 peptide induces generation of CD4+CD25+ regulatory T cells. Route of immunization has a critical role in the generation of these cells. Non-autoimmune mice BALB/c, C57BL/6 and NOR did not show up regulation of CD4+CD25+ regulatory T cells. These cells secreted large amounts of TGF-beta and TNF-alpha with little or no IFN-gamma and IL-10. Adoptive transfer of these CD4+CD25+ regulatory T cells into NOD-SCID mice completely prevented the adoptive transfer of disease by diabetogenic T cells. Although, non-self antigenic OVA (323-339) peptide immunization and in vitro culture with OVA (323-339) peptide does result in up regulation of CD4+CD25+ T cells, these cells did not prevent transfer of diabetes. Our study for the first time identified the generation of antigen-specific CD4+CD25+ regulatory T cells specifically in response to immunization with B:9-23 peptide in NOD mice that are capable of blocking adoptive transfer of diabetes. Our results suggest the possibility of using autoantigens to induce antigen-specific regulatory T cells to prevent and regulate autoimmune diabetes.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adoptive Transfer*
-
Animals
-
Antibodies, Monoclonal / pharmacology
-
Antigen Presentation / immunology
-
Antigens, CD / metabolism
-
Antigens, Differentiation, T-Lymphocyte / metabolism
-
CD3 Complex / immunology
-
CD4 Antigens / immunology*
-
CD4 Antigens / metabolism
-
Coculture Techniques
-
Diabetes Mellitus, Type 1 / immunology*
-
Drug Administration Routes
-
Female
-
Glycosuria / etiology
-
Glycosuria / urine
-
Immune Tolerance / immunology
-
Insulin / administration & dosage
-
Insulin / immunology*
-
Insulin / pharmacology
-
Interferon-gamma / metabolism
-
Interleukin-10 / metabolism
-
Islets of Langerhans / cytology
-
Islets of Langerhans / pathology
-
L-Selectin / metabolism
-
Lectins, C-Type
-
Leukocyte Common Antigens / metabolism
-
Lymph Nodes / cytology
-
Lymphocyte Activation / immunology
-
Mice
-
Mice, Inbred BALB C
-
Mice, Inbred C57BL
-
Mice, Inbred NOD / immunology
-
Mice, SCID
-
Ovalbumin / immunology
-
Ovalbumin / pharmacology
-
Peptide Fragments / administration & dosage
-
Peptide Fragments / immunology*
-
Peptide Fragments / pharmacology
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1
-
Receptors, Interleukin-2 / immunology*
-
Receptors, Interleukin-2 / metabolism
-
Spleen / cytology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / metabolism
-
Transforming Growth Factor beta / metabolism
-
Tumor Necrosis Factor-alpha / metabolism
-
Vaccination
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antigens, Differentiation, T-Lymphocyte
-
CD3 Complex
-
CD4 Antigens
-
CD69 antigen
-
Insulin
-
Lectins, C-Type
-
OVA 323-339
-
Peptide Fragments
-
Receptors, Interleukin-2
-
Transforming Growth Factor beta
-
Tumor Necrosis Factor-alpha
-
insulin B (9-23)
-
L-Selectin
-
Interleukin-10
-
Interferon-gamma
-
Ovalbumin
-
Leukocyte Common Antigens
-
Protein Tyrosine Phosphatase, Non-Receptor Type 1